Anal fissure is a small tear or cut in the skin of anal canal. It causes pain and bleeding during and after bowel movements. Anal fissures can occur due to constipation, straining during bowel movements, and other infections. Treatment options for anal fissure include topical nitroglycerin, calcium channel blockers, botulinum toxin injections, and surgery. Topical nitroglycerin acts as vasodilator to relax muscle fibers and sphincter to relieve pain during bowel movement. Calcium channel blockers work by blocking calcium channels to relax anal sphincter and reduce pressure in anal canal. Botulinum toxin injections temporarily paralyze muscles of internal anal sphincter to relieve pain and pressure. Surgery involves partial cutting or removal of internal anal sphincter for chronic fissures.
Market key trends:
One of the key trends in the anal fissure treatment market is rising awareness and diagnosis. Previously, many cases of anal fissures went undiagnosed due to lack of awareness and stigma associated with anal health issues. However, growing internet use and online health information has improved awareness about various ano-rectal conditions including anal fissures. This has encouraged more people to seek medical help for symptoms of anal fissures. As a result, diagnosis and treatment rates have increased over the years. Also, companies in this market are focusing on educational campaigns to promote awareness and early diagnosis of anal fissures. This is expected to drive further growth of the anal fissure treatment market during the forecast period.
The global Anal Fissure Treatment Market Size is estimated to be valued at US$ 1,039.3 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Threat of new entrants: Low. Anal fissure treatment market requires high R&D investments and regulatory approvals which make it difficult for new players to enter.
Bargaining power of buyers: Moderate. Few big pharmaceutical companies dominate the market, however growing awareness and availability of generic drugs increases bargaining power of buyers.
Bargaining power of suppliers: Low. Major pharma companies have established global supply networks for raw materials giving them an advantage over suppliers.
Threat of new substitutes: Low. No major substitute treatments exist currently for anal fissures.
Competitive rivalry: High. Large players compete intensely on brand recognition, innovation and pricing.
The global anal fissure treatment market is expected to witness high growth, exhibiting a CAGR of 5.3% over the forecast period, due to increasing prevalence of anal fissures and rising healthcare expenditure.
Regionally, North America is expected to dominate the market during the forecast period. This is attributed to growing awareness about anal fissure treatment and rising demand for minimally invasive therapies. However, Asia Pacific is projected to exhibit the highest CAGR during the forecast period due to increasing healthcare spending and the expanding medical tourism industry in the region.
Key players operating in the anal fissure treatment market are Allergan, Novartis, Pfizer, Takeda Pharmaceutical Company, Cook Medical, Medtronic, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Sanofi, Merck, Abbott Laboratories, Bayer, Astellas Pharma, Aurobindo Pharma, Ferring Pharmaceuticals, Salix Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Boehringer Ingelheim. Major players are focusing on new product launches and geographical expansion to strengthen their market presence.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it